AMRX vs. LLY
AMRX (Amneal Pharmaceuticals, Inc.) and LLY (Eli Lilly and Company) are both stocks. Both are in the Healthcare sector — AMRX in Drug Manufacturers - Specialty & Generic, LLY in Drug Manufacturers - General. Over the past 10 years, AMRX returned -5.11%/yr vs 32.12%/yr for LLY. Their 0.24 correlation means their historical movements had little consistent relationship.
Performance
AMRX vs. LLY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, AMRX achieves a 45.40% return, which is significantly higher than LLY's 7.26% return. Over the past 10 years, AMRX has underperformed LLY with an annualized return of -5.11%, while LLY has yielded a comparatively higher 32.12% annualized return.
AMRX
- 1D
- -0.97%
- 1M
- 6.82%
- 6M
- 33.92%
- YTD
- 45.40%
- 1Y
- 133.97%
- 3Y*
- 79.45%
- 5Y*
- 30.02%
- 10Y*
- -5.11%
- ALL TIME*
- 11.78%
LLY
- 1D
- -0.53%
- 1M
- -5.36%
- 6M
- 11.14%
- YTD
- 7.26%
- 1Y
- 51.77%
- 3Y*
- 37.33%
- 5Y*
- 37.67%
- 10Y*
- 32.12%
- ALL TIME*
- 16.04%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $32.37M | $32.67M | $30.54M | |
| $2.62B | $2.84B | $3.35B |
AMRX vs. LLY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
AMRX Amneal Pharmaceuticals, Inc. | 45.40% | 59.09% | 30.48% | 205.03% | -58.46% | 4.81% | -5.19% | -64.38% | -18.74% | 25.66% |
LLY Eli Lilly and Company | 7.26% | 40.25% | 33.30% | 60.91% | 34.26% | 66.08% | 31.04% | 16.14% | 40.45% | 17.83% |
Correlation
The correlation between AMRX and LLY is 0.34, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.34 |
Correlation (3Y) Balances recent behavior with more history. | 0.26 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.20 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.20 |
Correlation (All Time) Calculated using the full available price history since Jan 15, 2009 | 0.24 |
The correlation between AMRX and LLY shifts across timeframes, from 0.20 (10 years) to 0.34 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
AMRX:
$5.85B
LLY:
$1.08T
AMRX:
$0.48
LLY:
$28.16
AMRX:
37.97
LLY:
40.80
AMRX:
1.32
LLY:
0.82
AMRX:
1.92
LLY:
14.27
AMRX:
182.01
LLY:
32.99
AMRX:
$3.12B
LLY:
$72.25B
AMRX:
$1.23B
LLY:
$59.75B
AMRX:
$447.79M
LLY:
$32.97B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AMRX vs. LLY — Risk / Return Rank
AMRX
LLY
AMRX vs. LLY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Amneal Pharmaceuticals, Inc. (AMRX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AMRX | LLY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.60 | ||
| Sortino ratioReturn per unit of downside risk | +2.57 | ||
| Omega ratioGain probability vs. loss probability | 1.58 | 1.28 | +0.30 |
| Calmar ratioReturn relative to maximum drawdown | 6.07 | 2.44 | +3.63 |
| Martin ratioReturn relative to average drawdown | 15.13 | 6.60 | +8.52 |
Loading charts...
Drawdowns
AMRX vs. LLY - Drawdown Comparison
The maximum AMRX drawdown since its inception was -97.52%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for AMRX and LLY.
Loading charts...
Drawdown Indicators
| AMRX | LLY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.52% | -68.24% | -29.28% |
Max Drawdown (1Y)Largest decline over 1 year | -22.25% | -23.18% | +0.93% |
Max Drawdown (3Y)Largest decline over 3 years | -26.80% | -34.48% | +7.68% |
Max Drawdown (5Y)Largest decline over 5 years | -78.29% | -34.48% | -43.81% |
Max Drawdown (10Y)Largest decline over 10 years | -95.93% | -34.48% | -61.45% |
Current DrawdownCurrent decline from peak | -64.30% | -7.02% | -57.28% |
Average DrawdownAverage peak-to-trough decline | -54.42% | -19.17% | -35.25% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.91% | 8.56% | +0.35% |
Volatility
AMRX vs. LLY - Volatility Comparison
Amneal Pharmaceuticals, Inc. (AMRX) has a higher volatility of 9.86% compared to Eli Lilly and Company (LLY) at 8.88%. This indicates that AMRX's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| AMRX | LLY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.86% | 8.88% | +0.98% |
Volatility (6M)Calculated over the trailing 6-month period | 25.71% | 27.69% | -1.98% |
Volatility (1Y)Calculated over the trailing 1-year period | 33.29% | 38.37% | -5.08% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 50.81% | 32.64% | +18.17% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 65.25% | 30.37% | +34.88% |
Dividends
AMRX vs. LLY - Dividend Comparison
AMRX has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.56%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AMRX Amneal Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.56% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
Financials
AMRX vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Amneal Pharmaceuticals, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AMRX vs. LLY - Profitability Comparison
AMRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Amneal Pharmaceuticals, Inc. reported a gross profit of 334.51M and revenue of 796.20M. Therefore, the gross margin over that period was 42.0%.
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Eli Lilly and Company reported a gross profit of 15.64B and revenue of 19.80B. Therefore, the gross margin over that period was 79.0%.
AMRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Amneal Pharmaceuticals, Inc. reported an operating income of -1.30M and revenue of 796.20M, resulting in an operating margin of -0.2%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Eli Lilly and Company reported an operating income of 9.19B and revenue of 19.80B, resulting in an operating margin of 46.4%.
AMRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Amneal Pharmaceuticals, Inc. reported a net income of 57.66M and revenue of 796.20M, resulting in a net margin of 7.2%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Eli Lilly and Company reported a net income of 7.40B and revenue of 19.80B, resulting in a net margin of 37.4%.
Frequently Asked Questions
AMRX and LLY have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AMRX has higher volatility (9.86%) compared to LLY (8.88%). In terms of maximum drawdown, AMRX dropped -97.52% vs LLY's -68.24%.
AMRX currently has the higher Sharpe Ratio (4.08 vs 1.48), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for AMRX and LLY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer